93 related articles for article (PubMed ID: 8511300)
1. Hepatobiliary contrast material: a magic bullet for sensitivity and specificity?
Mitchell DG
Radiology; 1993 Jul; 188(1):21-2. PubMed ID: 8511300
[No Abstract] [Full Text] [Related]
2. [Magnetic resonance imaging of the liver: what kind of contrast agents?].
De Gaspari A; De Cobelli F; Del Maschio A
Radiol Med; 2001 Sep; 102(3):109-21. PubMed ID: 11677451
[TBL] [Abstract][Full Text] [Related]
3. [Manganese-DPDP in the MR tomography of malignant liver tumors. The initial results with a new hepatobiliary contrast agent].
Steudel A; Layer G; Kraheck H; Hartlapp J; Reiser M
Rofo; 1992 May; 156(5):460-4. PubMed ID: 1596550
[TBL] [Abstract][Full Text] [Related]
4. Contrast-enhanced MR imaging of the liver.
Saini S
Radiology; 1992 Jan; 182(1):12-4. PubMed ID: 1727273
[No Abstract] [Full Text] [Related]
5. [Magnetic resonance tomography of the hepatobiliary system: indications, limitations and outlook].
Vogl TJ; Hammerstingl R; Schnell B; Eibl-Eibesfeldt B; Peqios W; Lissner J
Bildgebung; 1992 Dec; 59(4):195-9. PubMed ID: 1292771
[TBL] [Abstract][Full Text] [Related]
6. Manganese-DPDP as a hepatobiliary contrast agent in the magnetic resonance imaging of liver tumors. Results of clinical phase II trials in Germany including 141 patients.
Rummeny E; Ehrenheim C; Gehl HB; Hamm B; Laniado M; Lodemann KP; Schmiedel E; Steudel A; Vogl TG
Invest Radiol; 1991 Nov; 26 Suppl 1():S142-5; discussion S150-5. PubMed ID: 1808111
[No Abstract] [Full Text] [Related]
7. Detection of liver metastases from gastrointestinal cancer: comparision of high resolution MnDPDP enhanced MRI and FDG-PET.
Kalva SP; Sahani DV; Ryan D; Fischman AJ; Hahn PF; Mueller P; Saini S
Acad Radiol; 2005 May; 12 Suppl 1():S17-20. PubMed ID: 16106540
[No Abstract] [Full Text] [Related]
8. Liver lesion detection and characterization with sequential use of hepatobiliary contrast agent mangafodipir trisodium and gadolinium-DTPA in a single imaging protocol.
Sahani DV; Saini S; Kalra MK; Michael M; Hahn PF
Acad Radiol; 2002 Aug; 9 Suppl 2():S460-2. PubMed ID: 12188308
[No Abstract] [Full Text] [Related]
9. New contrast agents for imaging the liver.
Helmberger T; Semelka RC
Magn Reson Imaging Clin N Am; 2001 Nov; 9(4):745-66, vi. PubMed ID: 11694436
[TBL] [Abstract][Full Text] [Related]
10. Breast carcinoma metastases to the liver simulating cirrhosis.
Burkill GJ; King LJ; Scurr E; Healy JC
Radiology; 2002 Dec; 225(3):917; author reply 917-8. PubMed ID: 12461279
[No Abstract] [Full Text] [Related]
11. Uptake of mangafodipir trisodium (MnDPDP) by hepatocellular carcinoma: correlation with unenhanced imaging findings and histopathologic features.
Chezmar JL; Redvanly RD; Sewell CW
Acad Radiol; 1996 Aug; 3 Suppl 2():S413-4. PubMed ID: 8796617
[No Abstract] [Full Text] [Related]
12. Hepatocellular tumors: characterization with Mn-DPDP-enhanced MR imaging.
Rofsky NM; Weinreb JC; Bernardino ME; Young SW; Lee JK; Noz ME
Radiology; 1993 Jul; 188(1):53-9. PubMed ID: 8390072
[TBL] [Abstract][Full Text] [Related]
13. The role of hepatocyte-specific contrast agents in hepatobiliary magnetic resonance imaging.
Burke C; Alexander Grant L; Goh V; Griffin N
Semin Ultrasound CT MR; 2013 Feb; 34(1):44-53. PubMed ID: 23395317
[TBL] [Abstract][Full Text] [Related]
14. Clinical hepatic imaging with paramagnetic positive enhancers.
Bernardino ME
Magn Reson Med; 1991 Dec; 22(2):334-8; discussion 343-6. PubMed ID: 1812367
[No Abstract] [Full Text] [Related]
15. A segmental hyperintensity area in the liver shown by delayed MR images with Mn-DPDP.
Suto Y; Weinreb JC; Rofski NM
J Comput Assist Tomogr; 1996; 20(4):647-9. PubMed ID: 8708073
[TBL] [Abstract][Full Text] [Related]
16. Soluble-type hepatobiliary contrast agents for MR imaging.
de Haën C; Gozzini L
J Magn Reson Imaging; 1993; 3(1):179-86. PubMed ID: 8428085
[No Abstract] [Full Text] [Related]
17. Detection of neuroendocrine liver metastases with MnDPDP-enhanced MRI.
Rockall AG; Planche K; Power N; Nowosinska E; Monson JP; Grossman AB; Reznek RH
Neuroendocrinology; 2009; 89(3):288-95. PubMed ID: 19023191
[TBL] [Abstract][Full Text] [Related]
18. [MRT of the liver. Clinical significance of nonspecific and liver-specific MRT contrast agents].
Ba-Ssalamah A; Happel B; Kettenbach J; Dirisamer A; Wrba F; Längle F; Schima W
Radiologe; 2004 Dec; 44(12):1170-84. PubMed ID: 15551031
[TBL] [Abstract][Full Text] [Related]
19. Mangafodipir trisodium injection (Mn-DPDP). A contrast agent for abdominal MR imaging.
Rofsky NM; Earls JP
Magn Reson Imaging Clin N Am; 1996 Feb; 4(1):73-85. PubMed ID: 8673718
[TBL] [Abstract][Full Text] [Related]
20. Mangafodipir trisodium (MnDPDP)-enhanced magnetic resonance imaging of the liver and pancreas.
Wang C
Acta Radiol Suppl; 1998; 415():1-31. PubMed ID: 9571956
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
